Mazdutide

See source wording

under the skin · daily · for 12 weeks

Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)PHASE2, PHASE3 · NCT07718126

“The dosing schedule follows a 12-week step-up titration regimen starting at 2 mg q1w for Weeks 1-2, increasing to 4 mg q1w for Weeks 3-4 if gastrointestinal tolerated, and reaching a target dose of 6 mg q1w from Week 5 to Week 12 if gastrointestinal tolerated.”

3 mg

under the skin · weekly · for 52 weeks

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementNA · NCT07517042

“Mazdutide is administered subcutaneously at 3.0 mg once weekly for 52 weeks during the weight maintenance period..”

See source wording

under the skin · weekly · for 24 weeks

A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and ObesityPHASE3 · NCT06184568

“Once-weekly injections of gradually increased doses of IBI362, subcutaneously (SC)，starting dose is IBI362 2.0 mg, continuous After 4 weeks of administration, increase to IBI362 4.0 mg.”

See source wording

under the skin · weekly · for 16 weeks

Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With SemaglutideNA · NCT07713992

“Subjects switch from previous semaglutide 1.0 mg weekly to mazdutide 4 mg immediately, with no washout period.After 16-week initial treatment phase, subjects with \<30% reduction in liver fat content from baseline will have mazdutide dose titrated up to 6 mg weekly as per study protocol..”

See source wording

under the skin · weekly · for 24 weeks

Efficacy of Mazdutide for Treating PCOSPHASE1, PHASE2 · NCT06519656

“In the initial 4 weeks, the subjects are given Mazdutide 2mg once weekly.”

See source wording

under the skin · weekly

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightPHASE2 · NCT06124807

“Participants received once-weekly subcutaneous Mazdutide with dose escalation until the target dose (3 or 6 mg) was achieved, starting at 1.5 mg from Weeks 0-3, followed by 3 mg from Weeks 4-31, then 6 mg from Weeks 32-48..”

See source wording

under the skin · every 4 weeks

Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe ObesityNA · NCT07135141

“The treatment begins with a starting dose of 2.0 mg, followed by a titration schedule increasing by 2.0 mg every 4 weeks (2.0 mg → 4.0 mg).”

See source wording

under the skin · weekly · for 4 weeks

Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)PHASE4 · NCT07654062

“Arm 1 (4 mg): titration from 2 mg QW (weeks 0-4) to 4 mg QW (weeks 5-24).”

See source wording

under the skin · weekly

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)PHASE3 · NCT07083154

“The starting dose is 2.0 mg administered once weekly (QW).”

See source wording

under the skin · weekly · for 4 weeks

Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityPHASE4 · NCT07657676

“Mazdutide administered subcutaneously once weekly, starting at 2 mg for 4 weeks, then escalated to 4 mg for 4 weeks, and then to 6 mg thereafter until week 52..”

400 mcg/kg

mice · under the skin

Mazdutide Ameliorates Non-Alcoholic Fatty Liver Disease by Modulating Endoplasmic Reticulum StressJournal not recorded · 2026

“Methods: A NAFLD mouse model was induced by a 12-week high-fat diet, followed by a 4-week treatment with subcutaneous Mazdutide (100, 200, or 400 μg/kg).”

400 mcg/kg

mice · under the skin

Mazdutide Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Modulating Endoplasmic Reticulum Stress, Improving Lipid Metabolism and Alleviating Inflammation.Pharmaceuticals (Basel, Switzerland) · 2026

“Methods: A MASLD mouse model was induced by a 12-week high-fat diet, followed by a 4-week treatment with subcutaneous Mazdutide (100, 200, or 400 μg/kg).”